START FREE TRIAL

Is The Devon + Coterra $21 Billion Merger About Growth — Or Running Out of Rock?

Devon Energy just announced a $21.4 billion all-stock acquisition of Coterra, positioning itself as one of the largest U.S....

Is Apple Outflanking Meta With This Q.AI Move?

Apple acquired Israeli startup Q.AI for close to $2B, locking down patents around “facial skin micro movements” that enable...

Ascendis Pharma Becomes M&A Target Again—European Suitors In Play?

Ascendis Pharma (NASDAQ:ASND) has suddenly become one of the hottest tickers in biotech circles after its shares surged 7.5%...

PayPal Buys Cymbio—What It Really Means For The Future Of AI Shopping

PayPal is acquiring Cymbio, a Tel Aviv-based platform that helps brands sell across agentic commerce channels. This pushes PayPal...

Boston Scientific Penumbra Acquisition: The $15 Billion Gamble That Could Dominate Neurovascular Markets

If you're wondering what Boston Scientific (NYSE:BSX) has been up to lately, buckle up. On January 15, the medtech...

Merck Revolution Medicines Acquisition: The $30 Billion Pipeline Gamble That Could Pay Off

Merck (NYSE:MRK) is making headlines again, this time for reportedly circling Revolution Medicines (NASDAQ:RVMD) in what could be one...

Snowflake Acquires Observe AI: The Boldest Move In Cloud Observability Yet!

Snowflake (NYSE:SNOW) just made a quiet but intriguing move that could reshape how enterprises handle observability at scale. On...

Meta Acquires Manus: The Real Reason Behind Zuckerberg’s $2 Billion AI Gamble

Meta Platforms (NASDAQ:META) just made another bold AI move. In a deal reportedly valued north of $2 billion, Meta...

Niagen NR Patent Acquisition Unlocks Massive Pharma Potential—But There’s a Catch!

If you blinked, you may have missed one of the more intriguing biotech moves of the year. Niagen Bioscience...

Howmet Buys CAM: The $1.8 Billion Bet That Could Reshape Aerospace

On December 22, 2025, Howmet Aerospace (NYSE:HWM) announced plans to acquire Consolidated Aerospace Manufacturing (CAM) from Stanley Black &...

BioMarin Amicus Acquisition: A $4.8 Billion Bet on Rare Disease Domination

BioMarin Pharmaceutical (NASDAQ:BMRN) just made its boldest move in years—unveiling a $4.8 billion all-cash acquisition of Amicus Therapeutics. The...

WBD Contested Takeover: The $100B Deal the Board May Walk Away From

The battle for Warner Bros. Discovery (NASDAQ:WBD) just escalated. Despite Paramount’s $30 all-cash hostile bid, WBD’s board is preparing...